Sign in
Taking people in United StatesNo phase

Studies ublituximab safety in older adults with relapsing multiple sclerosis

Observes infection rates in older adults with relapsing multiple sclerosis receiving ublituximab.

Key facts

Who runs it
Neurology Center of New England P.C.
Where
Foxborough, United StatesSee the site
Trial code
Registry title
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Status
Recruiting
People taking part
20 people, planned
Started
13 Aug 2024
Expected to end
30 Sept 2027
Type of study
Observational
Treatments tested
  • Ublituximab
Record updated
18 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for older adults aged 55-80 with relapsing multiple sclerosis who are starting ublituximab or started it within the last 6 months.

Age
55-80 years old
Sex
All sexes can join.
Disease stage
Relapsing forms of multiple sclerosis (RMS), diagnosed by the 2017 Revised McDonald criteria.
Earlier treatment
Starting ublituximab soon, or first dose given no more than 6 months before joining, as set by the local label.

Main reasons for not taking part

  • Taking part in another interventional MS trial right now
  • First ublituximab dose more than 6 months ago
  • Past life-threatening infusion reaction to an anti-CD20 therapy
  • Ongoing serious viral, bacterial or fungal infection needing long-term treatment
  • Repeated infections in the 6-12 months before starting ublituximab

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Signed informed consent
  • Aged 55-80 years old
  • Diagnosis of RMS according to the 2017 Revised McDonald criteria
  • Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label

Who cannot take part

  • Received initial dose of ublituximab more than 6 months prior to study entry
  • Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab
  • History of life-threatening infusion reaction on any anti-CD20 therapy
  • Active participation in an interventional clinical trial for MS

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 80 years old?

Where in United States

  • Neurology Center of New England P.C.Foxborough, United StatesContact: Rachel ODonnellTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

Treatments tested

  • Ublituximab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Plain-language title
Studies ublituximab safety in older adults with relapsing multiple sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06681623, who can take part
Record updated
18 November 2024